Brief: Lipigon Announces Positive Results From Preclinical Study For Lipid-Lowering Drug Candidate Lipisense

Lipigon Pharmaceuticals AB

02/12/2021 08:32

Dec 2 (Reuters) - Lipigon Pharmaceuticals AB  LPGO.ST :
    * LIPIGON ANNOUNCES POSITIVE RESULTS FROM PRECLINICAL STUDY
FOR
LIPID-LOWERING DRUG CANDIDATE LIPISENSE
    * 28-DAY TOXICOLOGY STUDY SHOWED THAT ALL DOSE LEVELS WERE
WELL
TOLERATED.
    * RESULTS, AS EXPECTED, DO NOT SHOW ANY SAFETY ISSUES
    * WE WILL CONTINUE ACCORDING TO PLAN WITH START OF PHASE I
STUDY
DURING Q2 OF 2022

Source text for Eikon:  ID:nBQNqL8df 
Further company coverage:  LPGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))